DaVita Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by DaVita Inc. on May 19, 2021. The report addresses corporate governance changes regarding the Board of Directors effective as of the filing date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters.
Material Changes
- Director Departure: Shawn Guertin notified the Board of his resignation as a director, Chair of the Audit Committee, and member of the Nominating and Governance Committee. His departure is due to his new role as Executive Vice President and CFO of CVS Health.
- Board Size Reduction: The Board approved a reduction in its size from nine to eight members.
- Committee Reassignments:
- Barbara Desoer was appointed to the Audit Committee and will no longer serve on the Compliance and Quality Committee.
- Paula Price was appointed as Chair of the Audit Committee.
- John Nehra was appointed to the Nominating and Governance Committee.
- 2021 Annual Meeting: Mr. Guertin will not be a director nominee for the election scheduled for June 10, 2021.
Outlook and Risks
Management confirmed that Mr. Guertin's departure is not the result of any disagreement with the Company. The Board is currently engaged in an ongoing process to select one or more new directors to fill the vacancy.
Key Facts for Investor Verification
- Verify the timeline for the appointment of a new director to replace Shawn Guertin.
- Confirm the composition of the Audit Committee following the reassignments of Barbara Desoer and Paula Price.
- Review the 2021 Annual Meeting proxy statement to confirm the updated list of director nominees.